Research exploring the mechanism by which peanut allergy develops as well as a potential desensitization treatment for peanut allergic individuals were among study findings presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia this month.
THURSDAY, March 20 (HealthDay News) -- Research exploring the mechanism by which peanut allergy develops as well as a potential desensitization treatment for peanut allergic individuals were among study findings presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia this month.
S.M.H. Chan, M.D., of King's College in London, England, and colleagues used skin and gastrointestinal homing memory T-cell markers to explore the mechanism by which individuals become sensitized to peanuts. The researchers hypothesize that sensitization to peanut through the skin may predispose to the development of peanut allergy, while oral sensitization leads to tolerance.
In a second study, Scott D. Nash, M.D., and colleagues at Duke University in Durham, N.C., investigated whether peanut oral immunotherapy could be used to desensitize peanut allergic children to peanut protein. The researchers treated 13 peanut allergic children with a three-phase regimen of peanut oral immunotherapy followed by an open food challenge of peanut flour. Eight patients had no symptoms in response to the food challenge, and the other five experienced mild allergic symptoms only.
"Peanut oral immunotherapy, we feel, is safe and effective for peanut-allergic patients, and we feel that our immunologic findings for peanut oral immunotherapy are similar to what we find for other forms of oral immunotherapy, Nash said.
Copyright © 2008 ScoutNews, LLC. All rights reserved.
At-risk adolescents with depression less likely to endorse suicidal thoughts on questionnaire
May 6th 2024Investigators sought to evaluate characteristics of adolescents with a history of depression who do not endorse risk via the PHQ item 9, which is commonly used to screen for self-harm and suicide risk.
Dupilumab safe, effective for up to 1 year for atopic dermatitis in infants, preschool children
May 3rd 2024According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.